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Natural killer (NK) cells are members of the innate immunity that respond rapidly to 
provide the first line of defense against pathogen invasion and cancer.  NK cells are 
produced in the bone marrow and home to the spleen, blood, liver, and lymph nodes 
where they exist in small numbers that are maintained by homeostasis. Few soluble 
factors have been identified to play a role in these process.  Of these soluble factors, 
the only well-characterized one is interleukin (IL)-15 and its role as a positive regulator 
of NK cell production and proliferation.  Little is known, however, about factors that 
negatively regulate NK cell homeostasis.  Transforming growth factor-beta (TGF-β) is 
known to be a potent immunosuppressing cytokine that affects many cell types.  Our lab 
has found that functional inactivation of TGF-β receptor (TGF-βR) signaling in a 
CD11cdnR transgenic mouse model results in an increase in NK cell numbers, 
suggesting that TGF-β is a negative regulator of NK cell production and proliferation.  
Using bromodeoxyuridine labeling method, I observed significant increase in 
proliferation rates of NK cells in CD11cdnR mice compared to littermate controls. 
Subsequently, I conducted a set of in vitro experiments using Annexin V and PI labeling 
and different IL-15 treatment conditions to determine the difference in IL-15 requirement 
for survival and proliferation between wild type and TGF-β-resistant NK cells.  My 
findings demonstrate that in the absence of TGF-βR signaling, NK cells proliferate more 
vigorously and the threshold for IL-15 required for survival is reduced.  These findings 
denote a previously undescribed function of TGF-β in regulating NK cell homeostasis by 
inhibiting NK cell proliferation and increasing the threshold of IL-15 required for NK cell 





The immune system is composed of two arms - the innate and adaptive immunity - 
which function to protect the host from potentially harmful agents such as bacteria, 
viruses, parasites, and abnormal host cells (Murphy et al., 2008).  Traditionally, innate 
immunity refers to a variety of short-lived myeloid and lymphoid cells that include 
granulocytes, mast cells, NK cells, dendritic cells, and macrophages.  These cells carry 
out a rapid, non-specific response to pathogen invasion (Murphy et al., 2008).  These 
cells perform their immune function through a limited repertoire of germline-encoded 
receptors (Vivier et al., 2011).  In contrast, adaptive immunity refers to slow, specific 
responses carried out by two types of lymphocytes, T and B cells, which express a large 
repertoire of antigen receptors produced by site-specific somatic recombination on the T 
cell receptor and antibody/B cell receptor (Murphy et al., 2008; Vivier et al., 2011).  
Recent findings characterizing NK cell receptors, however, demonstrate that NK cells 
express antigen-specific receptors and memory-like qualities resulting in increased 
specificity and more robust secondary responses to infections (Sun et al., 2009). Taken 
together, these findings suggest that NK cells represent an evolutionary bridge between 
the innate and adaptive immunity.  The role of NK cells as a first line of defense against 
tumors and a diverse range of pathogens further conclusively demonstrates the 
significance of NK cells and the importance of further studies on NK cells. 
 
NK cells - what is in the name? 
NK cells are large granular lymphocytes that are classically associated with the innate 
immune system because of their role in providing a rapid, non-specific response to 
pathogen invasion and cancer.  NK cells are identified by the expression of molecular 
markers such as CD122, NK1.1, CD49b (DX5), NKp46, CD11c, and a vast repertoire of 
inhibitory and activating receptors (Spits and Lanier, 2007).  Since these receptors are 
also expressed by other cell types, however, unambiguous NK cell identification can 
only be accomplished by the expression of a combination of these receptors rather than 
by the sole expression of one of these receptors.  To this end, NK cells can be identified 
as CD3-NK1.1+CD122+ cells in C57BL/6 mice or CD3-DX5+CD122+ cells in other strains 
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that do not express NK1.1 such as Balb/c strain.  The inclusion of CD3- cells is 
necessary to exclude natural killer T cells, the only other well-characterized cell type 
that is NK1.1+CD122+ (Di Santo, 2006). However, recently NKp46 has been identified 
as a specific marker for all NK cells (Walzer et al., 2007). 
True to their name, NK cells are involved in defense against viral and bacterial 
infections and are specialized in killing infected cells and tumor cells by cytolytic and 
proinflammatory mechanisms (Lodoen and Lanier, 2006).  Although initially believed to 
perform nonspecific killing, NK cells have been found to employ a combination of 
inhibitory and activating receptors to perform killer effector functions (Lodoen and 
Lanier, 2006; Raulet, 2004; Yokoyama, 2008). 
Originally, the missing-self hypothesis was proposed as a mechanism by which 
NK cells identified target cells by the absence of major histocompatibility complex 
(MHC) class I receptors (Karre et al., 1986).  MHC class I receptors are expressed by 
most cell types and typically present a self-antigen that marks the cell as self (Murphy et 
al., 2008).  The principle behind the missing-self hypothesis is that inhibitory receptors 
expressed on the surface of NK cells specifically recognize self MHC class I molecules.  
If NK cells encounter a cell and do not recognize MHC class I molecules, then they will 
carry out killer effector functions on this cell (Ljunggren, 1990; Raulet, 2004}.  These 
inhibitory receptors include Ly49 receptors in mice, killer immunoglobulin-like receptors 
(KIRs) and leukocyte immunoglobulin-like receptors (LIRs) in humans, and CD94-NKG2 
receptors in both species.  Lack of, or otherwise abnormal, MHC Class I expression is 
often associated with infection or transformation (Raulet, 2004).  The mechanism 
behind the alteration of MHC class I expression due to infection, transformation, or other 
forms of stress is not perfectly understood, but it is thought that viral infection often 
results in the downregulation of MHC Class I molecules as a means of immune evasion 
from CD8+ cytotoxic T cells and that the missing-self recognition by NK cells was 
developed as a counter-response by the immune system (Raulet and Vance, 2006). 
The missing-self hypothesis has been refined after studies have demonstrated 
that, similar to other lymphocytes, NK cells must be triggered by a combination of 
activating and costimulatory receptors to become activated and lyse target cells or 
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produce effector cytokines (Lanier, 2006; Raulet and Vance, 2006).  To this end, 
stimulatory receptors expressed on the surface of natural killer cells such as NKG2D, 
NKp46, NKp44, and NKp30 have been identified to recognize ligands which are 
specifically upregulated by tumor cells, virally infected cells, and stressed cells 
(Diefenbach and Raulet, 2003; Raulet, 2004).   
NK cells have also been found to employ other activating receptors that directly 
recognize viral proteins (Diefenbach and Raulet, 2003; Lodoen and Lanier, 2006).  This 
mode of identification is exemplified by the Ly49H receptor which recognizes the m157 
mouse cytomegalovirus (MCMV) viral protein (Raulet, 2004).  NK cells from C57BL/6 
mice normally express Ly49H receptors and are resistant to MCMV infection.  In 
contrast, BALB/c mice are deficient in Ly49H receptor expression and are susceptible to 
MCMV infection (Cheng et al., 2008; Fodil-Cornu et al., 2008).  These findings 
demonstrate the significance of the role of NK cells in providing protection against 
various pathogens by performing specific killing mediated by direct recognition of 
pathogen-associated molecular patterns (PAMPs). 
NK cells can also be activated by the upregulation of NKG2D ligands or 
cytokines that are the products of activated macrophages, dendritic cells, and other 
myeloid cells (Lodoen and Lanier, 2006; Raulet, 2004).  Cells can respond to pathogen 
infection by the recognition of PAMPs through pattern recognition receptors such as toll-
like receptors (TLRs).  PAMPs include bacterial lipopolysaccharides (LPS), flagellin, 
lipoteichoic acid, peptidoglycan, and nucleic acid variants normally associated with 
viruses.  PAMPs recognition activates cells and induces effector functions that ranges 
from proinflammatory, cell-mediated responses to humoral, antibody-mediated 
responses (Murphy et al., 2008).  One of the proinflammatory, cell-mediated responses 
that may result from PAMPs recognition involves activating NK cells by producing 
cytokines such as tumor necrosis factors (TNF), type I interferon (IFN), interleukin (IL) -
12, and IL-18 (Lodoen and Lanier, 2006; Raulet, 2004).  T cells and other cell types are 
also known to produce IL-2, IL-15, and other members of the common-gamma chain 




NK cell activation results in two main effector mechanisms that are used to control 
infection or kill infected or abnormal cells -the secretion of proinflammatory cytokines 
and direct lysis of cells (Lodoen and Lanier, 2006).  Proinflammatory cytokines 
produced include IFN-γ and TNF-α (Lodoen and Lanier, 2006).  The immune system 
uses inflammation as a means of simultaneous destruction and healing of tissue 
resulting in clearance of infections.  The release of proinflammatory cytokines recruits 
and activates cells such as granulocytes which release destructive inflammatory soluble 
factors and promotes a cell-mediated immune response involving T helper type 1 cells, 
CD8+ T cells, and macrophage activity (Murphy et al., 2008).  The lytic function of NK 
cells is mediated by the release of perforin and granzymes which attack and 
compromise the cell membrane of target cells (Lodoen and Lanier, 2006; Murphy et al., 
2008).  NK cells come preloaded with abundant granzyme A and mRNA encoding 
perforin and granzyme B which are translated upon NK cell activation.  This pre-existing 
pool of granzyme A and mRNA for granzyme B and perforin allows for the rapid 
response of NK cells to infected or abnormal cells (Fehniger et al., 2007).   
Recent studies have also demonstrated the capacity of NK cells to further shape 
and regulate the immune response generated to infection by secretion of immune-
suppressive cytokines such as IL-10, growth factors such as granulocyte macrophage 
colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), and 
IL-3, and chemokines such as CCL2, CCL3, CCL4, CCL5, CXCL1, and CXCL8 (Vivier 
et al., 2011).  Subsets of NK cells with increased specialization towards cytotoxic or 
proinflammatory effector functions have also been identified based on the expression of 
various surface markers such as CD11b, CD27, and CD127 (Di Santo, 2008). 
 
How do NK cells develop? 
NK cells are bone-marrow derived and share a common lymphoid progenitor with T and 
B cells (Hesslein and Lanier, 2011).  NK cell development primarily takes place in the 
bone, but subsets of NK cells have also been reported that develop in the thymus as 
well as fetal/newborn liver (Di Santo, 2006, 2008; Hesslein and Lanier, 2011; Sun and 
Lanier, 2011).  Thymic NK cells are identified by expression of CD127 and have 
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increased cytokine-producing capacity and reduced cytotoxicity (Vosshenrich et al., 
2006).  Fetal/newborn liver NK cells are identified by the expression of TRAIL while 
lacking DX5 and Ly49 receptors and have been associated with providing immune 
surveillance towards stressed or transformed cells during the fetal/newborn stage of life 
(Takeda et al., 2005). 
 
Models for the stages of NK cell development have been described based on the 
expression of various cell surface markers as illustrated in Figure 1.  Expression of 
CD122 by a non-stromal bone marrow cell has been correlated with commitment to the 
NK lineage and is referred to as an NK cell precursor (NKP), although it does not yet 
express NK cell lineage-specific markers (Di Santo, 2006; Sun and Lanier, 2011).  
CD122 refers to the IL2Rβ chain which is necessary for IL-15 recognition.  IL-15 is 
required for NK cell generation 
and survival (Colucci et al., 2003; 
Hesslein and Lanier, 2011).  Mice 
lacking IL-15 or its unique 
receptor component are highly 
deficient in NK cells (Jamieson et 
al., 2004).  Mice models deficient 
in the expression of the common 
gamma chain, which is another 
part of the IL-15 receptor 
complex, such as gamma chain 
knockout mice have no NK cells 
(DiSanto et al., 1995).   
 
 
Figure 1: Phenotypic markers of developing NK cells. NK precursors (NKP, stage A) are 
characterized by CD122 and NKG2D expression, but they lack other NK cell markers. 
Immature NK cells (iNK) upregulate NK1.1 and CD94 and transiently express TRAIL and 
CD51 (stages B and C). Ly49 receptor repertoires and DX5 are relatively late markers of NK 
cell differentiation expressed by mature NK cells (mNK,stages D and E). CD11b and CD43 
expression increase as NK cells differentiate, although effector functions do not depend on 
upregulation of these markers (Di Santo, 2006). 
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Similarly, mice with deficiencies in IL-15 production such as IL-15 knockout mice have 
dramatically reduced NK cell numbers (Kennedy et al., 2000).  This demonstrates the 
importance of CD122 in NK cell development and survival and is a likely reason for its 
early expression.  NKG2D is also expressed in the NKP stage (Figure 1).  The 
transcriptional factors Ets-1, Id2, Ikaros, and PU.1 have been identified in playing an 
important role in the generation of NKP through a mechanism that remains to be 
elucidated (Barton et al., 1998; Scott et al., 1994; Yokota et al., 1999).  This NKP stage 
denoted by CD122 and NKG2D has been associated with being the earliest-committed 
NK cell progenitor.  Recent studies, however, have identified a population of previously 
believed to be common lymphoid progenitors that are CD27+CD244+C-KIT+IL-7Rα+ but 
have down regulated Flk2 and are CD122-.  Researchers claim that this is a population 
of committed NK cell progenitors.  If true, these cells may be the earliest committed NK 
cell progenitor cells yet to be identified (Fathman et al., 2011). 
The next stage of NK cell development is the immature NK (iNK) cell stage and 
involves expression of NK1.1 and CD94.  The transcriptional factors Gata-3, IRF-2, and 
T-bet are important in the development and maturation of iNK (Samson et al., 2003; 
Taki et al., 2005; Vosshenrich et al., 2005b).   
Further maturation from iNK to mature NK (mNK) cells is characterized by the 
expression of DX5 and a vast repertoire of Ly49 receptors (Di Santo, 2006).  Mature NK 
cells progress through stages D, E, then F as they differentiate and upregulate CD11b, 
CD43, and various other activating and inhibitory receptors before reaching terminal 
maturation.  The functional differentiation leading to this terminal maturation is 
influenced by the transcriptional factors CEBP-γ, MEF, and MITF (Vosshenrich et al., 
2005b). Upon reaching terminal maturation at the F stage, NK cells leave the bone 
marrow and home to various peripheral tissues.  Mature NK cells are found in the bone 
marrow, spleen, blood, liver, lung, and lymph nodes where their numbers are tightly 
controlled by homeostasis (Di Santo, 2006; Sun and Lanier, 2011).   
NK cell precursors and immature NK cells have also been found in other tissues 
such as spleens and lymph nodes that suggest that NK cells may also develop in 
peripheral tissues, and recent studies have identified NK cell subsets in various 
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peripheral tissues (Di Santo, 2008).  One such case is with NK22 cells in the gut which 
are distinct from conventional NK cells in function and expression of many NK cell 
surface markers except for NKp46 (Colonna, 2009; Spits and Di Santo, 2011).  The 
designation of these cells as NK cells begs the question of what is necessary for cells to 
be classified as NK cells.   
 
How are NK cells maintained?  
Not much is known about the actual mechanism of maintaining NK cell numbers in the 
periphery compared to other cell types such as T cells.  The main factor known for 
playing a major role in peripheral NK cell homeostasis is IL-15 (Jamieson et al., 2004; 
Ranson et al., 2003). IL-15 is a member of the common-gamma chain cytokine family.  
As depicted in Figure 2, members of this cytokine family signal through a receptor 
complex consisting of an alpha chain complexed with the common-gamma chain.  This 
receptor complex then mediates signal transduction through JAK1 and JAK3 and 
different STAT molecules (Meazza et al., 2011).  IL-15 and IL-2 share the IL-2 receptor 
(IL-2R) β chain.  Both IL-2 and IL-15 have been demonstrated to promote NK cell 
proliferation and function which is attributed to this shared signaling pathway (Meazza et 
al., 2011).  However, studies of mice defective in IL-2, IL-2Rα, and IL-2Rβ have shown 
that IL-2 is not necessary in NK cell development, but IL-2Rβ is required mainly 
because of its role in IL-15 signaling (Cooper et al., 2002; DiSanto et al., 1995; Ranson 
et al., 2003; Vosshenrich et al., 2005a). 
The role of IL-15 as a proliferative and survival factor in NK cell homeostasis 
involves its role in mediating the maintenance of the anti-apoptotic factor bcl-2, 
protecting mature NK cells from apoptosis (Carson et al., 1997).  This is accomplished 
by the inhibition of Bim expression by a variety of mechanisms involving Erk-1/2 
phosphorylation or the phosphatidylinositol-3-OH kinase-dependent inactivation of the 
transcription factor Foxo3a (Huntington et al., 2007).  IL-15 also promotes NK cell 
survival by upregulation of Mcl-1 (Huntington et al., 2007). Adoptive transfer 
experiments and bromodeoxyuridine (BrdUrd) labeling have been used to demonstrate 
that splenic NK cells incorporate BrdUrd much more slowly than previously anticipated 
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with a half-life of about 17 days compared to the previous notions of the half-life only 
being about 1 day (Jamieson et al., 2004).  These studies have also demonstrated that 
although IL-15 is necessary for survival of NK cells and induces proliferation of NK cells, 
it is not necessary for homeostatic proliferation of NK cells (Jamieson et al., 2004).  
Further adoptive transfer experiments have demonstrated that NK cells typically have a 
half-life of about one week but rapidly disappear within 48 hours in the absence of IL-15 







Other members of the common-gamma chain cytokine family have also been identified 
in playing roles in NK cell homeostasis, differentiation, and function.  To this end, IL-4 
has been shown to inhibit NK cell function by negatively influencing NK/dendritic cell 
cross-talk and T helper type 1 functions while favoring T helper type 2 responses 
(Marcenaro et al., 2005).  IL-7 has also been shown to play a role in NK cell 
Figure 2: Family of the common cytokine-receptor γc. Each cytokine binds to a 
specific α chain, which forms a receptor complex with the γ c. In case of IL-2 and IL-15, 
trimeric high affinity complexes, which include common IL-2Rβ and γ c chains, can be 
formed. Each receptor complex mediates signal transduction through JAK1 and/or 
JAK3 and different STAT molecules. Tyr-phosphorylated STAT dimers regulate 
transcription of specific cytokine-sensitive genes.  (Meazza et al., 2011). 
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differentiation by supporting the differentiation of hematopoietic stem cells into lymphoid 
progenitor cells and by promoting the development of specific NK cell subsets, although 
these functions remain to be further elucidated (Cella et al., 2010; Satoh-Takayama et 
al., 2010).  Finally, studies have shown that although IL-21 has been shown to promote 
NK cell proliferation and survival, it may antagonize IL-15-induced proliferation and 
survival of NK cells by promoting the terminal differentiation of NK cells, but this remains 
poorly understood (Brady et al., 2010; Kasaian et al., 2002). 
 
NK cells and TGF-β what is the relationship? 
TGF-β is a member of the transforming growth factor-beta superfamily which consists of 
members such as TGF-β 1, TGF-β 2, TGF-β 3, bone morphogenetic protein, inhibins, 
and activins (Li and Flavell, 2008).  As depicted by Figure 3, members of the TGF-β 
superfamily signal through the TGF-βRI and TGF-βRII receptors which dimerize and 
function as a serine-threonine kinase upon ligand binding, resulting in the 
phosphorylation of Smad2, followed by a signal cascade (Li and Flavell, 2008). 
 
Figure 3: Molecular Mechanism of TGF-β Superfamily Signaling. Heterotetrameric receptor 
complexes are activated by ligand dimers (red and green triangles) and phosphorylate downstream 
effectors, the R-Smads (Smad1/5/8/2/3). Phosphorylated R-Smads then form complexes with each 
other (right-hand side of figure) and/or the co-Smad, Smad4 (left-hand side of figure), and 
accumulate in the nucleus to regulate target gene transcription. The function of the mixed R-Smad 
complexes in the nucleus is not yet clear. Transcription factors (TF) cooperate with Smad 
complexes on DNA. Nonphosphorylated monomeric Smads shuttle in and out of the nucleus. 
Multimeric complexes dissociate after R-Smad dephosphorylation in the nucleus and shuttle back 
to the cytoplasm. This is a receptor activity monitoring system (Wu and Hill, 2009). 
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TGF-β is a versatile immunoregulatory cytokine secreted by many cell types with potent 
immunosuppressing functions as well as proinflammatory functions (Murphy et al., 
2008).  Its effects on regulating T cells in the adaptive immunity have been well studied, 
and TGF-β is known to suppress differentiation and proliferation of T helper type 1 and 
2 cells while promoting differentiation and proliferation of T regulatory and T helper type 
17 cells (Li and Flavell, 2008).  However, little is known about the specific role of TGF-β 
on the innate immunity and innate immune cells such as NK cells. 
Transforming growth factor-beta has been identified as a negative regulator of 
NK cell homeostasis is (Laouar et al., 2005).  Our lab has demonstrated that CD11cdnR 
mice with functional inactivation of TGF-βR signaling due to an overexpression of a 
dominant-negative truncated form of the TGF-β receptor type II (TGF-βRII) controlled by 
the CD11c promoter have an increased peripheral NK cell pool (Figure 4, left panel).  
NK cells typically constitute about 3% of the lymphocyte population in the spleen of wild 
type mice.  However, NK cells constitute about 10% in CD11cdnR mice (Figure 4, right 
panel).   
Figure 4:  Characterization of CD11c
dnR
 mice. Left: CD11c
dnR
 mice dominantly express a 
nonfunctional TGF-β receptor type II (TGF-βRII) in which the cytoplasmic domain of the 
receptor has been truncated.  This transgene is located on the CD11c promoter resulting 
in the functional inactivation of TGF-βR signaling in CD11c
+
 cells in these mice. Right: 
Functional inactivation of TGF-β signaling results in an increase in NK cell numbers in the 
periphery.  Splenic NK cells increase from 3% of splenic lymphoctyes in wild type 
C57BL/6 mice to 11% in CD11c
dnR
 C57BL/6 mice.  Data are representative of increase 





We posit that increased numbers of TGF-β-resistant NK cells in CD11cdnR mice is due 
to increased proliferation and/or survival due to the relief of TGF-β suppression.  To this 
end, I used BrdUrd labeling methods to compare proliferation rates of wild type and 
TGF-β-resistant NK cells in vivo.  TGF-β-resistant NK cells are expected to incorporate 
more BrdUrd during BrdUrd pulse treatment and lose BrdUrd expression more rapidly 
during the decay phase of BrdUrd treatment and analysis.   
 
We hypothesized that an increased proliferation in the absence of TGF-β inhibition may 
be associated with a decrease in the threshold of IL-15 required for survival and 
proliferation of TGF-β-resistant NK cells.  To this end, I used Annexin V and PI labeling 
in different culture conditions to determine the difference in IL-15 requirements for 
survival and proliferation of TGF-β-resistant NK cells in vitro. TGF-β-resistant NK cells 
are expected to survive and proliferate more vigorously than wild type NK cells in all 
treatment conditions.  Moreover, TGF-β-resistant NK cells are expected to survive in IL-
15 treatment conditions in which the concentration of IL-15 is too low to promote 
survival of wild type NK cells. 
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Figure 5:  Generation of CD11c
dnR
 mice.  
CD11c
dnR
 transgene construct. dnTGFβRII, gray 
box; rabbit β-globin gene exon 3 (Ex3), white box; 
plasmid CD11c promoter vector, black box. 
EXPERIMENTAL STRATEGY 
 
A/ Mouse Model 
A1.  CD11cdnR mouse model 
We used a CD11cdnR mouse model to study the effect of TGF-β on NK cells.  CD11cdnR 
mice have a dominant negative expression of the TGF-β receptor type II (TGF-βRII) in 
which the cytoplasmic domain of the TGF-βRII receptor has been truncated preventing 
phosphorylation of Smad2 which is the first step in the TGF-β signaling pathway 
(Laouar et al., 2005).  This transgene is under the control of the CD11c promoter 
resulting in the expression of this nonfunctional receptor by CD11c+ cells such as 
dendritic cells and natural killer cells (Figure 5). Overexpression of this nonfunctional 
TGF-β receptor results in the functional inactivation of TGF-β receptor signaling in all 








A2.  Generation of bone marrow (BM) chimera mice 
 Wild type C57BL/6 mice were obtained from the National Cancer Institute and used as 
recipient hosts for BM chimera mice.  Congenic markers were used to differentiate 
between TGF-β-resistant NK cells from CD11cdnR mice and wild type NK cells from wild 
type mice.  CD11cdnR CD45.1+ C57BL/6 mice generated from our lab were used as 
donors of TGF-β-resistant NK cells and were identified by the expression of CD45.1.  
Wild type CD45.2+ C57BL/6 mice obtained from the National Cancer Institute were used 
as donors of wild type NK cells and were identified by expression of CD45.2.  Recipient 
hosts were irradiated with 1000 Rads and received an i.v. injection of mixed bone 
marrow cells provided at 1:1ratio between wild type and CD11cdnR donor cells.  Six to 
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eight weeks post-transfer, composition of splenocytes mice was analyzed to ensure 









B/ NK Cell Proliferation 
B1.  Measuring proliferation using bromodeoxyuridine 
Bromodeoxyuridine (BrdUrd) is a thymidine analog that can be incorporated into DNA 
during the S phase of the cell cycle after administration by intraperitoneal injection or 
feeding in water.  BrdUrd incorporation can then be detected by flow cytometry by using 
fluorochrome conjugated anti-BrdUrd antibodies (Figure 7).  Since BrdUrd is 
incorporated into DNA during the S phase of the cell cycle, detecting BrdUrd 
incorporation can be used to determine the frequency of cells that have entered the S 
phase of the cell cycle and are actively proliferating.  Monitoring BrdUrd incorporation 
over time can then be used to compare proliferation rates of cell populations.  Similarly, 
monitoring the loss of BrdUrd expression after cessation of BrdUrd treatment can be 
used to compare proliferation rates of cell populations (Wilson, 2000).  Two methods of 
BrdUrd treatment and analysis – pulse and decay – were used to compare proliferation 




Figure 6:  Analysis of mixed BM chimeras.  (A) BM cells from wild type and CD11c
dnR
 mice were 
mixed at a 1:1 ratio and transferred into wild type C57BL/6 recipient mice to generate BM chimera.  
(B) FACS plot shows the frequency of NK cells generated in mixed BM chimeras 8 weeks post-
















B2.  BrdUrd Treatment and Staining Optimization 
Prior to performing the actual experiments, BrdUrd treatment and staining was tested by 
observing BrdUrd incorporation of thymocytes.  T cells are known to proliferate 
vigorously as they go through development in the thymus (Ciofani and Zuniga-Pflucker, 
2007).  We hypothesized that this robust proliferation would be a good model for testing 
reagents and procedures for the BrdUrd experiments.  Wild type C57BL/6 mice received 
an i.p. injection of 2 mg BrdUrd and administered water with 1 mg/mL BrdUrd overnight 
(about 16 hours).  Mice received another i.p. injection of 2 mg/mL BrdUrd 4 hours 
before sacrificing.  Thymuses were harvested and FACS staining was performed using 





Figure 7:  BrdUrd incorporation and revelation.  (A)  BrdUrd is a thymidine analog that incorporates 
into the DNA of cells during the S phase of the cell cycle.  Picture was modified from 
http://www.bdbiosciences.com/research/apoptosis/analysis/index.jsp (B) BrdUrd is revealed by flow 
cytometry after performing surface staining, cell fixation/permeabilization, DNA degradation, and 
staining of BrdUrd with fluorochrome-conjugated anti-BrdUrd antibody.  (C) Cells that are actively 
cycling are identified by BrdUrd incorporation. 
A B C 
Figure 8:  BrdUrd incorporation in thymocytes.  Wild type 
mice were injected i.p. with 2 mg BrdUrd for overnight. 
Subsequently, thymocytes were isolated and detection of 
BrdUrd was performed according the manufacturer kit. 





 thymocytes.  Results are representative of 
multiple trials with a total of n=6 mice. 
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The trials on thymocytes demonstrate that BrdUrd treatment and staining procedure 
planned worked well.  In each trial, ~30% of CD3-CD4+CD8+ thymocytes incorporated 
BrdUrd during the short-term overnight BrdUrd treatment (Figure 8). 
After having success with thymocytes, BrdUrd treatment was done on wild type 
C57BL/6 mice and staining was tested for splenic NK cells.  Mice received an i.p. 
injection of 2 mg BrdUrd every 12 hours for three days and administered water with 1 
mg/mL BrdUrd during the treatment period.  Spleens were harvested and FACS staining 
was performed using fluorochrome-conjugated anti-CD3, -NK1.1, -DX5, and -BrdUrd.  
Successful staining of BrdUrd incorporation of cycling NK cells prompted continuation 












B3.  Methods for BrdUrd Treatment 
Two methods of BrdUrd treatment were used to determine rates of proliferation of 
resting NK cells in the absence of TGF-βR signaling.  The pulse method involves 
continuous BrdUrd treatment and uses the accumulation of BrdUrd+ cells as a measure 
of proliferation.  The decay method involves treating with BrdUrd until a significant 
fraction of cells have incorporated BrdUrd and then monitoring the loss of BrdUrd 
expression as a measure of proliferation.  
 
BrdUrd Pulse: During the BrdUrd pulse treatment, wild type and CD11cdnR mice 
received an i.p. injection of 2 mg BrdUrd every 12 hours for 3 days in combination with 1 
Figure 9:  Detection of cycling NK cells using BrdUrd labeling method. Wild type mice were 
treated with BrdUrd for 3 days as described above. On day 3, mice were sacrificed and NK 







 phenotype. This staining and gating procedure was used for BrdUrd pulse 
and decay experiments. 
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mg/mL BrdUrd administered in water for a consecutive 10 days (Figure 10).  
Accumulation of BrdUrd staining was analyzed at different time points of this kinetics 
 
BrdUrd Decay: After pulse BrdUrd treatment described above (10 days), wild type and 
CD11cdnR mice were put back on normal water and BrdUrd staining was measured on 










B4.  Proof of principle - BrdUrd Pulse and Decay Controls 
BrdUrd incorporation by splenic dendritic cells was used as a control during the pulse 
and decay experiments. We used dendritic cells to set up this method because dendritic 
cells are endowed with high proliferate and turnover. Their numbers are replenished by 
a combination of vigorous proliferation by hematopoietic progenitors, monocytes, or 
local tissue resident cells (Merad and Manz, 2009).  Fluorochrome-conjugated anti-
CD19, -Class II, -CD11c, and -BrdUrd was used to analyze BrdUrd incorporation in 
dendritic cells. 
As expected, robust proliferation of dendritic cells resulted in massive 
accumulation of BrdUrd+ dendritic cells that can be observed early in BrdUrd treatment 
(Figure 11 A).  As expected, dendritic cells rapidly lost BrdUrd staining within 1 week 
after cessation of BrdUrd treatment and was almost undetectable 2 weeks later (Figure 
11 B).  These results serve as proof that BrdUrd treatment was successful and that 
BrdUrd pulse and decay methods described can succesfully translate cell proliferation 
based on incorporation and loss of BrdUrd.  
 
Figure 10: Diagram illustrating BrdUrd Pulse and Cessation. Mice received BrdUrd by i.p. 
injections every 12 hours for the first three days and by water throughout the whole treatment 
period as indicated by blue arrows.  Mice were sacrificed and BrdUrd incorporation was 

















C/ Cell Death and Survival 
C1.  Annexin V and Propidium Iodide 
Annexin V is a calcium-dependent ligand that binds to phosphatidylserine.  
Phosphatidylserine is typically expressed in the inside of a cell’s cytoplasmic 
membrane.  However, as cells undergo apoptosis, phosphatidyl serine is transferred to 
the extracellular side of the cytoplasmic membrane (Figure 12).  Based on this 
principle, Annexin V staining allows for the identification of apoptotic cells (van 
Engeland et al., 1996).  
Propidium iodide (PI) is a DNA-staining dye.  While Annexin V staining allows for 
the identification of apoptotic cells, it does not allow for differentiation of apopototic and 
necrotic cells.  However, as cells enter the later stages of apoptosis, the 
semipermeability of their plasma membranes becomes compromised, and PI is able to 
enter and stain DNA (Figure 12).  Thus, staining with both PI and Annexin V is 
necessary to differentiate between apoptotic and necrotic cells (Martin et al., 1995; 
Span et al., 2002). 
B 
Figure 11:  BrdUrd accumulation and loss in 
dendritic cells.  Dendritic cells proliferate vigorously 
and (A) incorporate BrdUrd rapidly during pulse 
treatment and (B) lose BrdUrd rapidly after 












C2. Annexin V and PI staining and IL-15 treatment optimization 
Prior to performing in vitro culture experiments, Annexin V staining procedures of 
splenic NK cells were tested and optimized.  Splenocytes were harvested from wild type 
mice and plated at 1 million cells/mL in RPMI media with 5% FCS and 1% PS/Glu.  
Cultures were incubated overnight in a 37°C incubator.   
FACS staining was performed using no buffer, a homemade buffer made in the 
lab, or buffer from BD Annexin V FITC Apoptosis Kit (catalog number 556547).  Annexin 
V staining worked best with the buffer from the kit and following the procedure provided 
in the kit (Figure 13).  For this reason, the BD Annexin V FITC kit staining procedure 
was used for experiments. 
 
Figure 13:  Optimization of Annexin V 
staining.   Annexin V is a calcium-
dependent ligand that requires a 
special buffer containing calcium for 
successful Annexin V FACS staining.  
The buffer from the BD Annexin V 
FITC Apoptosis Kit yielded better 
results than a homemade buffer. 
Figure 12:  Principle of Annexin V and PI staining.  Annexin V binds to phosphatidyl serine which is 
typically found on the cytoplasmic side of the plasma membrane.  Phosphatidyl serine translocates to the 
external cell surface during the early stages of apoptosis.  Staining for only Annexiin V does not allow for 
the differentiation of apoptotic and late-apoptotic/necrotic cells.  Counterstaining with PI allows for the 
differentiation of apoptotic and late-apoptotic/necrotic cells because PI is not able to enter the cell until the 
plasma membrane becomes compromised in the later stages of apoptosis.  (Image from IMGENEX  CytoGLOTM 
Annexin V-FITC Apoptosis Kit description http://www.imgenex.com/apop_kits_list.php?id=76) 
21 
 
After establishment of a working Annexin V staining procedure, Annexin V and PI 
counterstaining was tested using the BD Annexin V FITC Apoptosis Kit procedure.  
Splenocytes were harvested from wild type mice and plated at 1 million cells/mL in 
RPMI media with 5% FCS and 1% PS/Glu.  Cultures were incubated for 3 days in a 
37°C incubator.  Successful Annexin V and PI staining showed 3 populations of Annexin 









Finally, as a final test before performing the actual in vitro culture experiments, IL-15-
induced proliferation and survival of NK cells in vitro was tested using the culture 
conditions that would be used in the actual experiments.  Splenocytes were harvested 
from wild type mice and plated at 1 million cells/mL in RPMI media with 5% FCS and 
1% PS/Glu supplemented with 0, 1, 5, 10, 20, or 50 ng/mL IL-15.  Cultures were 
incubated for 7 days at 37°C.  As expected, IL-15 is essential in NK cell survival and 
induces proliferation if the threshold for IL-15 required is reached (Figure 15). 
 
 
Figure 15:  Effect of IL-15 test on Nk cell survival.  NK cell culture for 7 days with treatment of 0, 1, 
5, 10, 20, or 50 ng/mL IL-15. 
Figure 14:  Annexin V and PI optimizaiton.  Annexin V counterstaining 
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C3.  NK in vitro Culture Conditions 
Splenocytes were harvested from wild type, CD11cdnR, or BM chimera mice and plated 
at 1 million cells/mL in RPMI media with 5% FCS and 1% PS/Glu.  Cultures received 0, 
1, 5, 10, 20, or 50 ng/mL of IL-15 every 4 days.  Wild type cultures were also treated 
with 0 or 5 ng/mL of TGFβ.  Cultures were incubated in a 37°C incubator until harvested 
at days 3, 7, 10, and 14 for analysis of NK cell survival.  
 
RESULTS 
I.  Functional inactivation of TGF-βR signaling in CD11cdnR mice results in 
robust proliferation of NK cells at steady state 
 
A. TGF-β-resistant NK cells incorporate more BrdUrd than wild type NK cells during  
pulse BrdUrd treatment 
In order to study the difference in proliferation rates due to functional inactivation of 
TGF-βR signaling, bromodeoxuridine (BrdUrd) labeling was used to identify cells that 
are proliferating and actively cycling.  BrdUrd was administered to wild type and 
CD11cdnR mice by i.p. injections and feeding through water for 10 days.  BrdUrd 
incorporation was measured at 4 hours, 24 hours, and 10 days into BrdUrd pulse 
treatment (Figure 16).   
BrdUrd+ NK cells were almost undetectable (0.5%) in wild type mice at 4 hours 
into treatment whereas a small percentage (2.2%) of BrdUrd+ NK cells were detectable 
in CD11cdnR mice at 4 hours into BrdUrd pulse treatment.  Furthermore, the percent of 
BrdUrd+ NK cells is consistently higher in CD11cdnR mice compared to wild type mice in 
Figure 16:  BrdUrd treatment of wild type and CD11c
dnR
 mice.  Mice received i.p. injections of BrdUrd 
every 12 hours for the first 3 days of treatment and were administered BrdUrd in water throughout the 
10 day BrdUrd treatment duration as indicated by blue arrows.  BrdUrd incorporation was measured 
at 4 hours, 24 hours, 10 days, 17 days, 24 days, 31 days, and 38 days as indicated by red arrows. 
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each time point during the pulse treatment reaching a final accumulation of 42% 
BrdUrd+ NK cells in wild type mice compared to 48% BrdUrd+ NK cells in CD11cdnR 
mice (Figure 18).  These results suggest that TGF-β-resistant NK cells proliferate more 
vigorously and thus incorporate more BrdUrd during the pulse treatment.  This 
difference in proliferation rate can be observed even in the early hours of BrdUrd 
treatment.  It is interesting, however, that the difference in BrdUrd+ NK cells in wild type 
compared to CD11cdnR mice is not as dramatic towards the end of treatment suggesting 
other factors may be limiting the number of NK cells that can be labeled with BrdUrd. 
 
B. TGF-β-resistant NK cells lose BrdUrd expression more rapidly than wild type NK 
cells after cessation of BrdUrd treatment 
NK cells are known to undergo robust proliferation in the bone marrow during 
development and maturation prior to homing to peripheral tissues (Di Santo, 2006).  
Proliferation then slows considerably.  To differentiate from BrdUrd incorporation due to 
robust NK cell proliferation in the bone marrow and homeostatic proliferation in steady 
state, the BrdUrd continuous pulse treatment was followed with a BrdUrd decay 
analysis.  As cells proliferate after cessation of BrdUrd treatment, they will lose the 
BrdUrd they have incorporated.  BrdUrd treatment ceased after 10 days, and BrdUrd 
incorporation was measured at days 7, 14, 21, and 28 after cessation of BrdUrd 
treatment (Figure 16). 
The percentage of BrdUrd+ NK cells decreases much more dramatically in 
CD11cdnR mice compared to wild type mice after cessation of BrdUrd treatment.  The 
percentage of BrdUrd+ NK cells dropped to 45% of the starting percentage of BrdUrd+ 
NK cells after BrdUrd treatment within 1 week in CD11cdnR mice but only dropped to 
67% of the starting percentage of BrdUrd+ NK cells in the wild type mice (Figure 19).  
This drop is made even more significant by the higher starting point of BrdUrd+ NK cells 
in CD11cdnR mice (Figure 20).  This more rapid loss of BrdUrd+ NK cells in CD11cdnR 





II. Robust proliferation of TGF-β-resistant NK cells in CD11cdnR mice is cell 
autonomous 
To determine if the increased NK cell proliferation observed in CD11cdnR mice is cell 
intrinsic, BM chimera mice were generated using bone marrow from wild type and 
CD11cdnR mice mixed 1:1.  BrdUrd pulse and decay experiments were repeated in 
these BM chimera mice. 
 
A. Augmented BrdUrd incorporation of TGF-β-resistant NK cells during continuous 
pulse BrdUrd treatment is cell intrinsic 
To study if the increased incorporation of BrdUrd observed during continuous pulse 
BrdUrd treatment is cell intrinsic, 1:1 wild type to CD11cdnR BM chimera mice were 
generated in wild type C57BL/6 hosts.  BM chimera mice received BrdUrd pulse 
treatment for 14 days and BrdUrd incorporation was measured at 4 hours, 24 hours, 3 
days, 7 days, and 14 days into BrdUrd pulse treatment (Figure 17). 
A higher percentage of BrdUrd+CD45.1+ NK cells compared to BrdUrd+CD45.2+ 
NK cells was observed at each time point during BrdUrd pulse treatment in BM chimera 
mice with a final accumulation of 25.7% BrdUrd+CD45.2+ NK cells compared to 38.7% 
BrdUrd+CD45.1+ NK cells.  More than twice as many BrdUrd+CD45.1+ NK cells were 
observed in the first three days of treatment compared to BrdUrd+CD45.2+ NK cells 
(Figure 21).  Again, this difference in BrdUrd+ cells is not as great towards the end of 
the treatment period. Increased BrdUrd incorporation of TGF-β-resistant NK cells 
indicates that NK cell proliferation is increased due to functional inactivation of TGF-βR 
signaling in a cell intrinsic manner. 
Figure 17:  BrdUrd treatment of BM chimera mice.  Mice received i.p. injections of BrdUrd every 12 
hours for the first 3 days of treatment and were administered BrdUrd in water throughout the 14 day 
BrdUrd treatment duration as indicated by blue arrows.  BrdUrd incorporation was measured at 4 hours, 




B. Augmented loss of BrdUrd expression of TGF-β-resistant NK cells during decay 
BrdUrd analysis is cell intrinsic 
To determine if the rapid loss of BrdUrd observed during BrdUrd decay experiments is 
cell intrinsic, experiments were repeated in 1:1 wild type to CD11cdnR BM chimera mice 
generated in wild type C57BL/6 hosts.  BrdUrd treatment of BM chimera mice was 
stopped after 14 days, and BrdUrd incorporation was measured at days 7, 14, 21, 28, 
and 35 after cessation of BrdUrd treatment (Figure 17). 
The percentage of BrdUrd+CD45.1+ NK cells decreased much more dramatically 
than BrdUrd+CD45.2+ NK cells in BM chimera mice.  The percentage of 
BrdUrd+CD45.1+ NK cells dropped by almost 75% by day 7 after cessation of BrdUrd 
treatment whereas the percentage of BrdUrd+CD45.2+ NK cells only dropped by 20% 
(Figure 22).  Again, this drop is made more significant considering the higher starting 
value of BrdUrd+CD45.1+ NK cells compared to BrdUrd+CD45.2+ NK cells (Figure 23).  
These results indicate that the more rapid loss of BrdUrd+ NK cells in CD11cdnR mice is 
a cell intrinsic characteristic due to functional inactivation of TGF-βR signaling in NK 
cells. 
 
III. Functional inactivation of TGF-βR signaling decreases IL-15 requirement for 
NK cell proliferation and survival in CD11cdnR mice 
To examine the difference in IL-15 requirements of wild type and TGF-β-resistant NK 
cells, splenocytes from wild type and CD11cdnR mice were cultured in different IL-15 
treatment conditions.  In vitro culture studies demonstrated that TGF-β-resistant NK 
cells require less IL-15 for survival and proliferation than wild type NK cells (Figures 24-
26).  No NK cells were recovered from wild type splenocyte cultures with 1 ng/mL IL-15.  
However, treatment with 1 ng/mL IL-15 is enough to rescue and promote the expansion 
of NK cells in CD11cdnR splenocyte cultures to 8% of splenic lymphocytes recovered.  
Treatment of wild type splenocyte cultures with 5 ng/mL IL-15 was enough to rescue NK 
cells and promote a similar level of expansion of NK cells observed in treatment of 
CD11cdnR splenocyte cultures with 1 ng/mL IL-15.  Treatment with 5 ng/mL IL-15 
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resulted in a more massive expansion of NK cells to 20% of splenic lymphocytes 
recovered by day 8 and 40% by day 10 in CD11cdnR splenocyte cultures.  Little to no 
difference was observed when splenocytes from either wild type or CD11cdnR mice were 
cultured at 10 ng/mL of IL-15 with expansion being observed in both cultures.  However, 
expansion in NK cell numbers is observed at an earlier time point in the cultures of 
CD11cdnR splenocytes.  Interestingly, a greater expansion in NK cell numbers was 
observed in cultures of wild type splenocytes treated with 20 ng/mL of IL-15 with NK 
cells composing 40% of splenic lymphocytes recovered from wild type splenocyte 
cultures compared to 17% in CD11cdnR splenocyte cultures (Figures 24-26).  This 
suggests that TGF-β-resistant NK cells reach their maximal IL-15 requisite at a lower 
concentration of IL-15 than wild type NK cells and are detrimentally affected by excess 
IL-15 after this threshold has been reached.  Wild type NK cells similarly fared better 
than TGF-β-resistant NK cells treated with 50 ng/mL IL-15, although both types were 
negatively affected by the excess IL-15 and did not do as well as when treated with 20 
ng/mL IL-15 (Figures 24-26). 
 Addition of 5 ng/mL TGF-β to all cultures resulted in a drastic decrease in cells 
recovered from cultures of splenocytes from wild type mice.  Essentially no NK cells 
were recovered from cultures of wild type splenocytes treated with 0, 1, 5, 10, or 20 
ng/mL IL-15 as well as 5 ng/mL TGF-β.  Treatment with 50 ng/mL IL-15 rescued NK 
cells but was not able to induce NK cell expansion (Figures 24-26).   
Annexin V and PI data of CD3-NK1.1+DX5+ cells show that the majority of NK 
cells (>75%) recovered from cultures that received IL-15 treatment are live.  Most cells 
(~90%) recovered from cultures that received 0 ng/mL IL-15 were apoptotic or necrotic.  
Addition of 5 ng/mL TGF-β increased the percentage of apoptotic and necrotic cells in 
all treatment conditions (Figure 27).  These results serve as an affirmation that the NK 
cells recovered from the cultures were viable, live cells whose survival is attributed to 





IV. Decreased IL-15 requirement for NK cell proliferation and survival in CD11cdnR 
mice is cell autonomous 
To determine if in vitro culture results revealing a decreased threshold for IL-15 required 
for NK cell survival and proliferation is cell intrinsic, 1:1 wild type to CD11cdnR BM 
chimera mice were generated.  In vitro cultures were replicated suing splenocytes from 
these BM chimera mice.  Cultures of splenocytes from BM chimera mice demonstrate 
that increased potential for survival is cell intrinsic.  CD45.1+ cells originate from 
CD11cdnR donor mice.  CD45.2+ cells originate from wild type donor mice.  NK cell 
survival was observed in all cultures that were treated with IL-15.  Furthermore, 
expansion of NK cells was observed in cultures treated with 5, 10, 20, or 50 ng/mL IL-
15.  70% of NK cells recovered from cultures treated with 1 ng/mL IL-15 at all time 
points were CD45.1+.  Interestingly, except on day 7 when CD45.2+ cells compose 67% 
and 78% of NK cells in cultures treated with 5 or 10 ng/mL IL-15, respectively, little 
difference was observed between CD45.1+ and CD45.2+ NK cells in cultures treated 
with 5 or 10 ng/mL IL-15 with both populations composing about half of the NK cells 
recovered.  A higher proportion of the NK cells recovered from cultures treated with 20, 
or 50 ng/mL IL-15 were CD45.2+ supporting the observation of wild type NK cells doing 
better in conditions with higher concentrations of IL-15 (Figures 28-30). 
 Similar to results from separate wild type and CD11cdnR splenocyte cultures, 
Annexin V and PI data of CD3-NK1.1+DX5+ cells affirm that the majority of NK cells 
(>80%) recovered from BM chimera splenocyte cultures are live (Figure 31).  Taken 
together, these results suggest that TGF-β inhibits IL-15-induced NK cell survival and 











Two major outcomes from these results are that TGF-β-resistant NK cells have 
increased proliferation and decreased threshold for IL-15 required for survival. 
 
Increased capacity for NK cell proliferation in the absence of TGF-βR signaling 
The BrdUrd pulse and decay results demonstrate that proliferation is dramatically 
increased in TGF-β-resistant NK cells.  The increased proliferation rates of CD45.1+ 
cells from CD11cdnRCD45.1+ donor cells compared to CD45.2+ cells from wild type 
CD45.2+ C57BL/6 mice in the BM chimera mice demonstrates that the increased NK 
cell proliferation observed in CD11cdnR mice is a cell intrinsic characteristic due to 
functional inactivation of TGF-βR signaling.   
NK cells, in part due to their association with the innate immune system, have 
traditionally been assumed to be short-lived innate immune cells (Jamieson et al., 2004; 
Sun and Lanier, 2009).  However, recent studies have reported that NK cells persist 
longer than originally conceived (Jamieson et al., 2004).  Furthermore, reports of long-
lived, homeostatic and memory NK cells that are able to mount secondary responses 
and contribute to immune memory challenge previously conceived notions of NK cell 
longevity (Sun et al., 2010; Sun and Lanier, 2009). The persistence of BrdUrd+ NK cells 
long after BrdUrd treatment cessation supports these findings on the longevity of NK 
cells.   
Studies have demonstrated that it takes about 17 days to label half of the 
population of splenic NK cells with BrdU (Jamieson et al., 2004).  My results of BrdUrd 
incorporation of wild type NK cells from BrdUrd treatment of wild type and BM chimera 
mice agree with these findings, with the percentage of BrdUrd+ wild type cells slowly 
approaching 50% towards the end of BrdUrd treatment.  The decreased BrdUrd 
incorporation in BM chimera mice suggests that extrinsic factors may be inhibiting NK 
cell survival or proliferation in these mice.  Competition for limited resources and space 
may be one of these factors.  Adoptive transfer studies have reported that NK cells 
undergo massive proliferation upon transfer into a lymphopenic environment and that 
proliferation drastically decreases upon reconstitution and filling of available space.  
29 
 
This decrease is correlated with an increase in T and B cell proliferation which ultimately 
constitute a greater proportion of the splenic lymphocyte pool (Jamieson et al., 2004). 
The inability to label greater than 50% of NK cells with BrdUrd in CD11cdnR mice 
suggests that there is an increase in NK cell turnover in these mice.  Turnover refers to 
both proliferation as well as death.  This increase in turnover rate may be due to the 
spacial limitations imposed on the cells in the face of increased proliferation or a 
restriction on available nutrients required to sustain NK cell survival.  These findings 
suggest a role of TGF-β in both suppressing NK cell proliferation while promoting NK 
cell survival in order to maintain NK cell numbers in steady state conditions. 
TGF-β-resistant NK cells proliferate much more rapidly and amount to a much 
higher percentage of BrdUrd+ NK cells during BrdUrd treatment.  The percentage of 
BrdUrd+ NK cells drops dramatically within 1 week after cessation of BrdUrd treatment, 
especially in BM chimera mice.  The dramatic decrease in BrdUrd+ TGF-β-resistant NK 
cells after cessation of Brdurd treatment may be attributed to a combination of 
increased NK cell proliferation as well as death in the absence of TGF-βR signaling.  A 
combined theory of increased proliferation as well as death may explain the more 
dramatic and rapid loss of BrdUrd expression during the BrdUrd decay experiments 
compared to accumulation during pulse treatment experiments. 
The decreased difference in BrdUrd+ TGF-β-resistant NK cells compared to wild 
type NK cells during BrdUrd pulse treatment in BM chimera mice suggests that extrinsic 
factors may also affect NK cell homeostasis in these mice.  These factors may include 
soluble factors produced by CD11c+ cells such as dendritic cells transferred from the 
CD11cdnR donor mice.  These cells may have increased effector functions due to 
functional inactivation of TGF-βR signaling that may influence NK cell proliferation.  
Dendritic cells can activate NK cells by trans-presentation of IL-15 (Huntington et al., 
2009).  It has also been hypothesized that natural killer cells also possess potential IL-
15 trans-presentation and cis-presentation capabilities that allow sustained IL-15 
stimulatory effects (Meazza et al., 2011).  It is possible that these IL-15 cis- and trans-
presentation functions are increased in CD11cdnR mice due to functional inactivation of 
TGF-βR signaling, contributing to the increased NK cell proliferation in CD11cdnR mice.  
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The increased proliferation that is still observed in TGF-β-resistant NK cells in BM 
chimera mice indicates that, although these extrinsic factors may also contribute to 
increased NK cell proliferation in CD11cdnR mice, functional inactivation of TGF-βR 
signaling results in a cell intrinsic increase in NK cell proliferation. 
The host being a wild type mouse may also affect the survivability of cells from 
CD11cdnR donor mice.  These factors affecting survivability may also be a reason for the 
much more dramatic drop in BrdUrd+ TGF-β-resistant NK cell numbers in BM chimera 
mice compared to CD11cdnR mice at day 7 after cessation of BrdUrd treatment.  Further 
studies using CD11cdnR mice as hosts are necessary to elucidate this phenomenon.  
Studies involving the transfer of sorted NK cells and using Rag-/-γc-/- mice which are 
deficient in NK cells and other lymphocytes would help elucidate questions about other 
extrinsic factors that may influence NK cell proliferation (DiSanto et al., 1995; Garcia et 
al., 1999). 
 
Functional inactivation of TGF-β signaling decreases the threshold of IL-15 
required for NK cell survival and proliferation in vitro 
TGF-β-resistant NK cells from CD11cdnR mice demonstrated a higher capacity for 
survival and proliferation at lower concentrations of IL-15 than wild type NK cells.  TGF-
β-resistant NK cells were able to survive and proliferate at 1 ng/mL IL-15 whereas little 
to no wild type NK cells were recovered at this treatment condition.  This could be 
observed in cultures of splenocytes from separate wild type and CD11cdnR mice.   This 
observation is confirmed as a cell intrinsic trait by the cultures of splenocytes from BM 
chimera mice.  Wild type NK cells demonstrated an increased capacity for survival and 
proliferation as the concentration of IL-15 increased.  At 20 ng/mL for TGF-β-resistant 
NK cells and 50 ng/mL IL-15 for both wild type and TGF-β-resistant NK cells, NK cells 
appeared to reach a threshold for IL-15 responsiveness.  Past this threshold, NK cells 
either have their survival and proliferation detrimentally affected by the excess IL-15 or 
they are outcompeted by other cells that also proliferate in response to IL-15 such as 
CD8+ cytotoxic T cells (Jakobisiak et al., 2011).  TGF-β-resistant NK cells reached this 
threshold of IL-15 at a lower concentration than wild type NK cells.  These results 
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suggest that TGF-β-resistant NK cells would be able to outcompete wild type cells 
because of their reduced nutrient requirements for survival and proliferation. This may 
be one reason for the increased splenic NK cell pool in CD11cdnR mice and the larger 
proportion of CD45.1+ NK cells in the BM chimera mice.  
Addition of TGF-β to wild type splenocyte cultures negated the IL-15-induced 
survival in cultures treated with 0, 1, 5, 10, or 20 ng/mL IL-15.  Treatment with 50 ng/mL 
IL-15 was able to overcome the inhibition imposed by TGF-β but not able to induce 
expansion of NK cells.  These findings further describe a role for TGF-β as an inhibitor 
of IL-15-induced NK cell survival and proliferation by a mechanism that remains to be 
identified.  These findings also suggest that this mechanism involves antagonistic TGF-
βR and IL-15R signaling that necessitates a prerequisite amount of stimulatory IL-15R 
signaling to overcome the inhibitory TGF-βR signaling in order to promote NK cell 
survival and inhibition.  Lifting of the inhibitory TGF-βR signaling in NK cells of CD11cdnR 
mice reduces the IL-15 required for survival and proliferation, allowing TGF-β-resistant 
NK cells to persist in the cultures with 1 ng/mL IL-15 whereas wild type NK cells were 
unable to survive in the nutrient-scarce environment. 
 The annexin V and PI results denote that the majority of NK cells recovered from 
cultures treated with 1, 5, 10, 20, or 50 ng/mL IL-15 were live.  In contrast, the majority 
of NK cells recovered from cultures without IL-15 treatment were apoptotic or necrotic.  
This observation again demonstrates that IL-15 was able to rescue and promote the 
survival of NK cells.  However, these results reveal flaws in the experimental 
procedures with regards to the indiscrimination of cell numbers and inability of 
identifying apoptotic or necrotic NK cells that have down regulated their NK1.1 and DX5 
receptors.  Higher percentages of apoptotic or necrotic cells were expected in cultures 
with lower concentrations of IL-15 that correspond with the decreased NK cells 
recovered from cultures under these treatment conditions.  However, there was little to 
no variability in the annexin V and PI results for cultures that received IL-15 because the 
annexin V and PI results are gated to the NK cells (CD3-NK1.1+DX5+) recovered.  
Regardless, the annexin V and PI results for cultures without IL-15 treatment and 
cultures that received 5 ng/mL TGF-β suggest that the annexin V and PI labeling was 
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successful.  The percentage of apoptotic and necrotic cells also increased upon addition 
of TGF-β, which was expected considering virtually no NK cells were recovered from 
these cultures.  However, since virtually no NK cells were recovered from these 
cultures, it is strange that the annexin V and PI data are saying that there are live cells 
rather than all apoptotic or necrotic cells as was observed in the 0 ng/mL cultures.  
These results epitomize the problem with indiscrimination towards cell numbers as a 
misleading factor in the annexin V and PI results obtained.  The indiscrimination 
towards cell numbers involved in this labeling method proves to be a limiting factor that 
will have to be addressed in future experiments and when performing further analysis of 
data from these experiments.  Still, the annexin V and PI results serve as an affirmation 
that the NK cells recovered are mostly viable, live cells whose survival is attributed to IL-
15 treatment.  Experimental procedures must also be refined in future experiments to 
allow for identification of NK cells that have down regulated their identification markers.  
Sorting and plating of NK cells instead of whole splenocytes may address some of 
these issues, but will prevent the characterization of the interplay of other splenocytes in 
IL-15-induced NK cell survival and proliferation.   
  
Functional inactivation of TGF-β signaling increases NK cell proliferation by 
reducing the threshold for IL-15 required for survival and proliferation 
The findings from the BrdUrd in vivo studies and the in vitro culture studies describe a 
role for TGF-β in inhibiting IL-15-induced NK cell survival and proliferation.  BrdUrd 
pulse and decay experiments demonstrate that TGF-β inhibits NK cell proliferation in 
vivo.  In vitro cultures with different concentrations of IL-15 demonstrate that TGF-β 
inhibits IL-15-induced NK cell survival and proliferation by increasing the threshold of IL-
15 required for survival and proliferation of NK cells in vitro.  Taken together, these 
findings suggest that the increased proliferation rates of TGF-β-resistant NK cells 
observed in vivo in the BrdUrd experiments may be attributed to the decreased IL-15 
requirements for proliferation due to the functional inactivation of TGF-βR signaling.  
The increased splenic NK cell pool in CD11cdnR mice may also be attributed to this 
increased proliferation rate due to decreased IL-15 requirements.  This decrease in IL-
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15 requirement for survival and proliferation also indicates that the suggested increase 
in cell death of TGF-β-resistant NK cells from BrdUrd experiments is likely due to 
spacial limitations rather than nutrient limitations, and that this suggested increase in 
cell death does not necessarily correlate with a decrease in the long-term survivability 
and viability of TGF-β-resistant NK cells.  These findings denote a previously 
undescribed function of TGF-β in inhibiting NK cell proliferation by disrupting IL-15 
induced survival and proliferation. 
 
TGF-β-resistant NK cells and NK cell therapies 
The increased proliferation and decreased IL-15 requirements of TGF-β-resistant NK 
cells suggests that these NK cells may be more effective as NK cell therapeutic agents 
than wild type NK cells. 
 NK cell therapy has been a popular candidate for cancer treatment.  Initially, the 
therapeutic potential for cancer was hindered by the inability of NK cells to effectively 
clear tumor cells that were identified as self (Geller and Miller, 2011).  However, recent 
studies involving allogeneic transplantation of NK cells have yielded promising results 
for NK cell immunotherapy against cancer.  In these studies, donor NK cells that may 
express KIR that do not recognize that HLA-class I alleles present on the recipient cells 
were able to mount an effective anti-leukemia response resulting in efficient lysis of 
leukemic cells a strong graft versus leukemia effect.  The alloreactive NK cells were 
also able to eliminate residual host dendritic cells, preventing graft-versus-host disease  
and graft rejection (Moretta et al., 2011). 
Even with advancements such as this, NK cell therapies are currently inhibited by 
the inability of NK cells to persist in large enough numbers and replenish themselves 
within a new host (Voskens et al., 2010).  To this end, studies that involve the 
development of ex-vivo expansion methods have been performed to try to overcome 
this barrier (Voskens et al., 2010).  The increased capacity of TGF-β-resistant NK cells 
to proliferate suggests that these cells have a higher potential than wild type NK cells of 
amounting to a large enough population size to achieve desired therapeutic treatment 
goals.  The decreased IL-15 requirement for survival and proliferation also suggests that 
34 
 
these cells will be able to outcompete endogenous NK cells and persist longer in the 
host environment.  The increased proliferation and decreased IL-15 requirement 
suggest that TGF-β-resistant NK cells may allow for sufficient in vivo expansion after 
allogeneic transfer, circumventing current requirements for ex-vivo expansion.   
TGF-β is also known to inhibit NK cell effector functions (Terme et al., 2008).  For 
instance, functional inactivation of TGF-βR signaling in NK cells of CD11cdnR mice has 
been correlated with an increased production of IFN-γ by NK cells (Laouar et al., 2005).  
This suggests that allogeneic transplantation of TGF-β-resistant NK cells would not only 
pose an increase in therapeutic potential due to a proliferative advantage, but also due 
to enhanced effector functions.  Further studies on differences in effector functions of 
TGF-β-resistant NK cells would elucidate their true immunotherapeutic potential.   
NK cells provide first-line defense against pathogen invasion by viruses, bacteria, 
and parasites.  NK cell protection against infections by viruses such as mouse and 
human cytomegalovirus, Sendai virus, Influenza A virus, and Ebola virus is associated 
with production of IFN-γ and other proinflammatory cytokines.  NK cell cytotoxicity is 
also important in protection against mouse cytomegalovirus (Iversen et al., 2005; Loh et 
al., 2005; Siren et al., 2004; Warfield et al., 2004).  The specific role of NK cells in 
bacterial and parasitic infection is even less understood.  However, studies suggest that 
their cytolytic and proinflammatory functions contribute to defense against infections by 
Mycobacterium tuberculosis, Psamodium falciparum, Trypanosoma cruzi, and Shigella 
flexneri (Artavanis-Tsakonas et al., 2003; Le-Barillec et al., 2005; Lieke et al., 2004; 
Vankayalapati et al., 2005).  The pluripotent role of NK cells in providing protection 
against a variety of pathogens suggests that NK cell immunotherapy using TGF-β-





Not much is currently known about the soluble factors that regulate NK cell 
homeostasis.  IL-15 is the only well-characterized soluble factor that has been identified 
to play a role in NK cell homeostasis.  Other studies have suggested that other 
members of the common-gamma chain cytokine family may also regulate NK cell 
homeostasis, but this remains not well defined (Meazza et al., 2011).  Here I present 
findings that demonstrate the role of TGF-β as a negative regulator of NK cell 
homeostasis by inhibiting proliferation and increasing the threshold for IL-15 required for 
NK cell survival and proliferation.  Earlier studies have reported a role of TGF-β in 
dampening NK cell effector functions (Laouar et al., 2005; Terme et al., 2008).  Taken 
together, these findings suggest that TGF-β-resistant NK cells may possess greater 
immunotherapeutic potential than wild type NK cells because of their increased 




These BrdUrd and in vitro culture studies have established a foundation for further 
characterization of TGF-β-resistant NK cells.  Using Rag-/-γc-/- wild type and CD11cdnR 
mouse models would help elucidate questions about extrinsic factors that may play a 
role in NK cell survival and proliferation.  Using IL-15-/- mice or other mouse models 
with deficient IL-15 signaling would clarify the interplay between TGF-β and IL-15 in 
regulating NK cell survival and proliferation in vivo.  Further in vitro studies using IL-15 
as well as other cytokines such as IL-12, IL-18, IL-21, IL-2, and IL-4 would also further 
elucidate the effect of TGF-β on the homeostasis and effector functions of NK cells.  
Further characterization of the role of TGF-β as an inhibitor of NK cell proliferation, 
survival, and effector functions would help advance the current knowledge regarding the 
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Figure 18: BrdUrd pulse treatment of wild type and CD11cdnR mice.  Functional 
inactivation of TGF-β receptor signaling results in a higher frequency of BrdUrd 
incorporation in TGF-β-resistant NK cells compared to wild type NK cells at each time 
point during the pulse BrdUrd treatment.  (A) FACS plots gated on CD3-NK1.1+ DX5+ 
cells. (B) Line graph representation of data from A.  Data are representative of n=6 wild 
type mice and n=6 CD11cdnR mice 
Figure 19:  BrdUrd decay in wild type and CD11cdnR mice.  Functional inactivation of 
TGF-β receptor signaling results in a more rapid loss of BrdUrd + NK cells in CD11cdnR 
mice compared to wild type mice.  (A) FACS plots gated on CD3-NK1.1+DX5+ cells.  (B)  
Line graph representing data from A.  (C) Line graph of data from A normalized with 
respects to values at Day 10 when BrdUrd treatment was stopped so that Day 10 
equals 100% BrdUrd+ NK cells. 
Figure 20: BrdUrd pulse and decay in wild type and CD11cdnR mice.  (A) Line graph 
with combined pulse and decay results from Figure 18 and Figure 19.  (B) Line graph of 
data from Figure 18 and Figure 19 normalized with respects to values at Day 10 when 
BrdUrd treatment was stopped so that Day 10 equals 100% BrdUrd+ NK cells. 
Figure 21:  Pulse treatment of BM chimeras.  Functional inactivation of TGF-β receptor 
signaling results in a higher frequency of BrdUrd incorporation in CD45.1+ TGF-β-
resistant NK cells compared to CD45.2+ wild type NK cells at each time point during the 
pulse BrdUrd treatment of BM chimera mice.  (A) FACS plots gated on CD3-
NK1.1+DX5+ cells.  (B)  Line graph representing data A.  (C) Line graph of data from A 
normalized with respects to values at Day 14 when BrdUrd treatment was stopped so 
that Day 14 equals 100% BrdUrd+ NK cells. 
Figure 22: BrdUrd decay in BM chimera mice.  Functional inactivation of TGF-β 
receptor signaling results in a more rapid loss of BrdUrd+ CD45.1+ NK cells than 
CD45.2+ NK cells in BM chimera mice. (A) FACS plots gated on CD3-NK1.1+DX5+ cells.  
(B)  Line graph representing data from A.  (C) Line graph of data from A normalized with 
respects to values at Day 14 when BrdUrd treatment was stopped so that Day 14 
equals 100% BrdUrd+ NK cells. 
Figure 23:  BrdUrd pulse and decay in BM chimera mice.  (A) Line graph with combined 
pulse and decay results from Figure 20 and Pulse treatment of BM chimeras.  
Functional inactivation of TGF-β receptor signaling results in a higher frequency of 
BrdUrd incorporation in CD45.1+ TGF-β-resistant NK cells compared to CD45.2+ wild 
type NK cells at each time point during the pulse BrdUrd treatment of BM chimera mice.  
(A) FACS plots gated on CD3-NK1.1+DX5+ cells.  (B)  Line graph representing data A.  
(C) Line graph of data from A normalized with respects to values at Day 14 when 
BrdUrd treatment was stopped so that Day 14 equals 100% BrdUrd+ NK cells. 
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Figure 22.  (B) Line graph of data from Figure 20 and Pulse treatment of BM chimeras.  
Functional inactivation of TGF-β receptor signaling results in a higher frequency of 
BrdUrd incorporation in CD45.1+ TGF-β-resistant NK cells compared to CD45.2+ wild 
type NK cells at each time point during the pulse BrdUrd treatment of BM chimera mice.  
(A) FACS plots gated on CD3-NK1.1+DX5+ cells.  (B)  Line graph representing data A.  
(C) Line graph of data from A normalized with respects to values at Day 14 when 
BrdUrd treatment was stopped so that Day 14 equals 100% BrdUrd+ NK cells. 
Figure 22 normalized with respects to values at Day 10 when BrdUrd treatment was 
stopped so that Day 10 equals 100% BrdUrd+ NK cells. 
Figure 24:  FACS plots of separate wild type and CD11cdnR in vitro splenocyte cultures.  
FACS plots of NK cells recovered from in vitro cultures of (A) wild type and (B) 
CD11cdnR splenocytes cultured with no TGFβ and 0, 1, 5, 10, 20, or 50 ng/mL IL-15.  (C) 
FACS plot of NK cells recovered from in vitro cultures of wild type splenocytes with 5 
ng/mL TGFβ and 0, 1, 5, 10, 20, or 50 ng/mL IL-15. 
Figure 25:  Line graph representation of wild type and CD11cdnR in vitro splenocyte 
cultures with data from Figure 24 with days as a function of concentration of IL-15.  (A) 
Combined graph of all days.  Graph of (B) day 3, (C) day 8, (D) day 10 (E) day 14. 
Figure 26:  Line graph representation of wild type and CD11cdnR in vitro splenocyte 
cultures with data from Figure 24 with IL-15 concentrations as a function of days.  (A) 
Combined graph of all concentrations.  Graph of (B) 0 ng/mL, (C) 1 ng/mL, (D) 5 ng/mL, 
(E) 10 ng/mL, (F) 20 ng/mL, (G) 50 ng/mL IL-15.   
Figure 27:  Annexin V and PI data of separate wild type and CD11cdnR in vitro 
splenocyte cultures.  Data is gated on CD3-NK1.1+DX5+.  Results from in vitro cultures 
of (A) wild type and (B) CD11cdnR splenocytes cultured with no TGFβ and 0, 1, 5, 10, 
20, or 50 ng/mL IL-15.  (C) Results from in vitro cultures of wild type splenocytes with 5 
ng/mL TGFβ and 0, 1, 5, 10, 20, or 50 ng/mL IL-15. 
Figure 28:  FACS plots of BM chimera in vitro splenocyte cultures with 0, 1, 5, 10, 20, 
or 50 ng/mL IL-15.  FACS plots of (A) NK cells recovered from in vitro cultures gated to 
total splenic lymphocytes and (B) the distribution of CD45.1+ and CD45.2+ NK cells 
gated to CD3-NK1.1+DX5+ cells. 
Figure 29:  Line graph representation of BM chimera in vitro splenocyte cultures with 
data from Figure 28 with days as a function of concentration of IL-15.  (A) Combined 
graph of all days.  Graph of (B) day 3, (C) day 7, (D) day 10 (E) day 14. 
Figure 30:  Line graph representation of BM chimera in vitro splenocyte cultures with 
data from Figure 24 with IL-15 concentrations as a function of days.  (A) Combined 
graph of all concentrations.  Graph of (B) 0 ng/mL, (C) 1 ng/mL, (D) 5 ng/mL, (E) 10 
ng/mL, (F) 20 ng/mL, (G) 50 ng/mL IL-15.   
44 
 
Figure 31:  Annexin V and PI data of BM chimeras in vitro splenocyte cultures.  Data is 
gated on CD3-NK1.1+DX5+.  Results from in vitro cultures of (A) mixed wild type and 
CD11cdnR cells from BM chimeras, (B) gated to CD45.2+ wild type cells, and (C) 
CD45.1+ CD11cdnR cells cultured with no TGFβ and 0, 1, 5, 10, 20, or 50 ng/mL IL-15. 
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Figure 22 A 
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Figure 23 A 






0 ng/mL 1 ng/mL 5 ng/mL 10 ng/mL 20 ng/mL 50 ng/mL 
Concentration IL-15 
0.1 1.0 1.2 1.4 1.1 1.6 
0 0.1 3.9 7.5 39.9 17.9 
0.1 0.1 8.5 28.7 58.9 9.3 












0 ng/mL 1 ng/mL 5 ng/mL 10 ng/mL 20 ng/mL 50 ng/mL 
Concentration IL-15 
0.7 6.5 4.2 4.0 2.6 3.0 
0 8.6 19.8 14.1 17.7 4.3 
0.1 8.0 43.7 33.3 16.8 3.2 







Gated on total splenic lymphocytes 
Figure 24 A Wild Type 






0 ng/mL 1 ng/mL 5 ng/mL 10 ng/mL 20 ng/mL 50 ng/mL 
Concentration IL-15 
0.1 0.6 1.7 1.7 2.0 1.4 
0 0 0.2 0.4 0.5 0.8 
0.1 0 0.1 0.1 0.2 0.5 








Gated on total splenic lymphocytes 
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Figure 25 A 
Figure 25 B Figure 25 C 
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Figure 27 A 
Figure 27 B 














5.2 2.4 12.7 11.7 7.4 5.3 
1.1 0.7 1.2 1.0 1.0 0.8 
0.4 1.2 33.5 23.3 10.7 1.9 
5.0 3.8 36.4 14.8 7.4 4.6 














17.6 66.1 26.6 15.9 14.7 15.5 
29.4 67.0 78.3 81.1 80.7 30.2 
70.8 79.0 64.9 67.3 75.0 78.2 
9.7 28.7 24.0 19.1 17.8 9.4 
42.6 70.1 32.6 41.8 26.7 30.0 
14.9 50.6 50.7 51.9. 42.7 24.6 
6.67 73.7 46.8 35.7 35.5 23.8 
60.0 49.9 55.6 47.0 70.8 21.0 
Gated on CD3-NK1.1+DX5+ cells 
Figure 28 A 
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